Navigation Links
Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
Date:9/24/2007

ogy to develop longer-acting, proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales. The CTP technology is applicable to virtually all proteins and Modigene is currently developing long-acting versions of human growth hormone, interferon beta and erythropoietin, which are in late preclinical development, as well as GLP-1. For more information on Modigene, visit http://www.modigeneinc.com.

Safe Harbor Statement: This press release contains forward-looking statements, including statements regarding the results of current studies and preclinical experiments and the effectiveness of Modigene's long-acting protein programs and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Modigene's business and prospects, including the risks that Modigene may not succeed in developing any commercial products based upon its long- acting protein technology, including any long-acting versions of human growth hormone, erythropoietin, interferon beta or GLP-1; that the long-acting products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The development of any products using the CTP platform technology could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical ind
'/>"/>

SOURCE Modigene Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/17/2014)... CHICAGO, Ill. , Nov. 17, 2014  AbbVie (NYSE: ... Global Healthcare Conference in London on ... president and chief financial officer, will make a formal presentation ... time.) A live audio webcast of the ... at www.abbvieinvestor.com .  An archived edition of the session ...
(Date:11/17/2014)... , Nov. 17, 2014   Wilson Therapeutics ... start of a Phase 2 clinical study to evaluate ... in Wilson Disease, a rare genetic disorder and designated ... process copper. "We are delighted to proceed ... as a next step in the development program for ...
(Date:11/16/2014)... AUSTIN, Texas , Nov. 16, 2014  Hanger, ... it is postponing the release of its third quarter ... earnings conference call to allow additional time for the ... The Company will release its third quarter financial results ... review of its third quarter financial statements. ...
Breaking Medicine Technology:Wilson Therapeutics Announces Start Of Phase 2 Study To Evaluate The Efficacy And Safety Of WTX101 In Newly Diagnosed Wilson Disease Patients 2Wilson Therapeutics Announces Start Of Phase 2 Study To Evaluate The Efficacy And Safety Of WTX101 In Newly Diagnosed Wilson Disease Patients 3
... Inc. , a company that manufactures and sells a ... in specific markets outside the United States through a ... new BIOSAFE-treated Ultra Sensitive facemasks begin to reduce microorganisms ... and have further proven to be effective against Influenza ...
... , NEW YORK, Oct. 13 Reportlinker.com ... is available in its catalogue. , ... Outlook to 2010: Marketing and Sales Strategies ... , http://www.reportlinker.com/p0154807/Reportlinker-Adds-Global-Drug-Manufacturing-Industry-Outlook-to-2010-Marketing-and-Sales-Strategies-and-the-Impact-of-Recession-and-Recovery.html ...
Cached Medicine Technology:BIOSAFE Launching In a New Specially-Treated Facemask Effective Against H1N1 Influenza 2BIOSAFE Launching In a New Specially-Treated Facemask Effective Against H1N1 Influenza 3BIOSAFE Launching In a New Specially-Treated Facemask Effective Against H1N1 Influenza 4Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 2Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 3Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 4Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 5Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 6Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 7Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 8Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 9Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 10Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 11Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 12Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 13Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 14Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 15Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 16Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 17Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 18Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 19Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery 20
(Date:11/18/2014)... Haelle HealthDay Reporter MONDAY, ... experience a severe abusive head trauma before the age of ... new study. In addition, among those who survive ... the study found. Abusive head trauma includes shaken baby ... suffers head injuries, according to background information in the study. ...
(Date:11/18/2014)... Dennis Thompson HealthDay Reporter ... Daily low-dose aspirin therapy may not have significant heart-health ... The study, which involved more than 14,000 Japanese people ... heart-related deaths or non-fatal heart attacks and strokes between ... "It indicates that primary prevention with daily low-dose ...
(Date:11/18/2014)... Dennis Thompson HealthDay Reporter , ... stroke patients can safely take aspirin combined with a blood-thinning ... increase a patient,s risk of early death, according to a ... American Heart Association in Chicago. The report was also published ... of data from more than a dozen clinical trials revealed ...
(Date:11/18/2014)... MONDAY, Nov. 17, 2014 (HealthDay News) -- Until recently, insect-transmitted ... America, but it has made its way to the United ... fatal illness is typically transmitted via the bite of the ... night. And now a new study suggests that common bedbugs ... bedbug can acquire and transmit the parasite. Our next step ...
(Date:11/17/2014)... CA (PRWEB) November 17, 2014 A ... thousands of patients throughout the country are turning back ... than ever before. This is because the company has ... to their already impressive collection of prescription and non-prescription ... who have incorporated Diet Doc’s best anti-aging ...
Breaking Medicine News(10 mins):Health News:Head Trauma in Abused Babies, Toddlers Can Have Lifelong Impact 2Health News:Head Trauma in Abused Babies, Toddlers Can Have Lifelong Impact 3Health News:Head Trauma in Abused Babies, Toddlers Can Have Lifelong Impact 4Health News:Daily Aspirin Fails to Help Older Hearts in Japanese Study 2Health News:Daily Aspirin Fails to Help Older Hearts in Japanese Study 3Health News:Long-Term Use of Aspirin Plus Blood Thinner Is Safe: Study 2Health News:Long-Term Use of Aspirin Plus Blood Thinner Is Safe: Study 3Health News:Bedbugs Could Be Potential New Source of Tropical Disease in U.S. 2Health News:Bedbugs Could Be Potential New Source of Tropical Disease in U.S. 3Health News:Best Anti-Aging Human Growth Hormone Therapy Safely and Naturally Restores Diet Doc Patients to More Youthful Levels 2Health News:Best Anti-Aging Human Growth Hormone Therapy Safely and Naturally Restores Diet Doc Patients to More Youthful Levels 3
... ... commitment to consumer privacy protection , ... Westlake Village, CA and San Francisco, CA (PRWEB) September 1, 2009 ... has been certified to display the TRUSTe Privacy Seal, which demonstrates its commitment to ...
... EDINBURGH, Scotland, September 1 Aircraft Medical,(Aircraft), the UK ... to its R&D, business development and sales teams since January ... staff is in line with the Company,s commitment to,expanding the ... business development and R&D activities. , ...
... The American Academy of Otolaryngology Head and ... only--national clinical practice guideline to help healthcare practitioners ... as dysphonia. The guideline emphasizes evidence-based management of ... prevalence of this common vocal health issue. ...
... , , DENVER, Aug. 31 ... of kidney care services for those diagnosed with chronic kidney disease ... leading health care industry publications, named Kent Thiry, Chairman and CEO ... Healthcare in 2009. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20020729/DAVITALOGO ) ...
... NASHVILLE, Tenn., Aug. 31 Cumberland Pharmaceuticals Inc. (Nasdaq: ... on hospital acute care and gastroenterology markets, today announced that ... Global Life Sciences Conference in New York at 11:00 a.m. ... provide an update on the Company and its Caldolor product, ...
... Pa., Aug. 31 Endo Pharmaceuticals (Nasdaq: ENDP ) announced today ... Thursday, Sept. 10, 2009, at 2:40 p.m. EDT. Alan Levin, Chief Financial ... , The presentation will be webcast live and can be accessed ... , , About Endo , ...
Cached Medicine News:Health News:The People's Medicine Community Certified to Display TRUSTe Privacy Seal of Approval 2Health News:The People's Medicine Community Certified to Display TRUSTe Privacy Seal of Approval 3Health News:Aircraft Reports Material Expansion and Staff Increase 2Health News:National guideline released for the treatment of hoarseness 2Health News:National guideline released for the treatment of hoarseness 3Health News:DaVita CEO Kent Thiry Honored as One of Modern Healthcare's 100 Most Powerful People in Healthcare 2Health News:Cumberland Pharmaceuticals to Present at UBS Global Life Sciences Conference in New York on September 21, 2009 2Health News:Endo Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference 2009 2
... end transcription services. Zodiac offers two ... either submitted over the phone via ... 24 hours a day, 7 days ... recorded on a digital handheld recorder ...
... Achieve high-speed productivity in the lab ... system, dedicated for pre- and post-analytical sorting ... HSS selectively decaps and then sorts primary ... to save time, labor, and eliminate ...
Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and ...
Similar to Model 530, but just 37 inches long and with only one drape....
Medicine Products: